REIG JOFRE acquires Leanbio and strengthens its vertical integration in biotechnology

Reig Jofre has consolidated its stake in Leanbio by increasing its shareholding from 47% to 85%, following the acquisition of shares valued at €3.5 million. The remaining 15% remains in the hands of the founding team and specialised shareholders. This transaction is part of Reig Jofre’s strategy to expand its business model towards an integrated biopharmaceutical structure covering everything from research to the industrial production of biological medicines, positioning itself as a key partner in the development of biotechnological products in Europe. With the integration of Leanbio, the company strengthens its ability to accelerate the market entry of new therapies and biosimilars, consolidating a unique platform in the sector.